Inductive Bio
Inductive Bio is an AI-driven drug discovery technology company based in Brooklyn, New York. Founded in 2022 by Josh Haimson and Ben Birnbaum, the company focuses on optimizing the compound development process in pharmaceuticals. It specializes in addressing ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) challenges for small molecules using advanced machine learning and generative chemistry. The flagship offering is the Compass platform, a human-guided virtual lab that conducts millions of in-silico experiments to predict drug properties before synthesis. This platform helps scientists identify promising drug candidates more efficiently. Inductive Bio also provides chemistry design software that allows biopharma teams to make real-time predictions during compound design, as well as proprietary machine learning models trained on a comprehensive ADMET dataset. The company aims to launch an AI-native Contract Research Organization (CRO) to further enhance its services in drug discovery.